Zacks: Analysts Expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Announce Quarterly Sales of $5.85 Billion

Brokerages predict that Teva Pharmaceutical Industries Limited (NYSE:TEVA) will report sales of $5.85 billion for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Teva Pharmaceutical Industries Limited’s earnings. The highest sales estimate is $6.12 billion and the lowest is $5.76 billion. Teva Pharmaceutical Industries Limited posted sales of $5.04 billion in the same quarter last year, which suggests a positive year-over-year growth rate of 16.1%. The company is scheduled to report its next earnings results before the market opens on Thursday, August 3rd.

On average, analysts expect that Teva Pharmaceutical Industries Limited will report full-year sales of $5.85 billion for the current fiscal year, with estimates ranging from $22.80 billion to $24.10 billion. For the next financial year, analysts anticipate that the business will report sales of $22.93 billion per share, with estimates ranging from $22.27 billion to $23.80 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Teva Pharmaceutical Industries Limited.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $1.06. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The company had revenue of $5.63 billion during the quarter, compared to analyst estimates of $5.69 billion. During the same quarter in the prior year, the company earned $1.20 earnings per share. The company’s revenue for the quarter was up 17.0% on a year-over-year basis.

Several research firms recently commented on TEVA. Jefferies Group LLC reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, July 25th. Maxim Group reissued a “hold” rating and set a $35.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $41.00 price target on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, July 18th. BTIG Research reissued a “neutral” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, April 6th. Finally, Wells Fargo & Company reissued a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Tuesday, June 27th. Fifteen research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $42.88.

Several large investors have recently bought and sold shares of TEVA. Schulhoff & Co. Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock valued at $372,000 after buying an additional 1,004 shares during the period. Heritage Investors Management Corp boosted its stake in Teva Pharmaceutical Industries Limited by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares during the last quarter. Bank Hapoalim BM boosted its stake in Teva Pharmaceutical Industries Limited by 9.2% in the first quarter. Bank Hapoalim BM now owns 11,673 shares of the company’s stock worth $375,000 after buying an additional 980 shares during the last quarter. Coastline Trust Co boosted its stake in Teva Pharmaceutical Industries Limited by 3.6% in the first quarter. Coastline Trust Co now owns 29,990 shares of the company’s stock worth $962,000 after buying an additional 1,040 shares during the last quarter. Finally, ST Germain D J Co. Inc. boosted its stake in Teva Pharmaceutical Industries Limited by 0.4% in the first quarter. ST Germain D J Co. Inc. now owns 69,183 shares of the company’s stock worth $2,220,000 after buying an additional 295 shares during the last quarter. Institutional investors own 56.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) Will Announce Quarterly Sales of $5.85 Billion” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2017/08/19/zacks-analysts-expect-teva-pharmaceutical-industries-limited-nyseteva-will-announce-quarterly-sales-of-5-85-billion-updated-updated.html.

Shares of Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.96% during mid-day trading on Friday, hitting $31.86. The company had a trading volume of 6,223,163 shares. The firm’s 50-day moving average price is $32.01 and its 200 day moving average price is $32.29. The company has a market capitalization of $32.34 billion, a P/E ratio of 6.20 and a beta of 0.46. Teva Pharmaceutical Industries Limited has a one year low of $27.59 and a one year high of $55.79.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries Limited (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit